3 August 2020 - BioCryst Pharmaceuticals today announced that the U.S. FDA has granted fast track designation for its oral factor D inhibitor, BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria.

According to the FDA, the purpose of the fast track designation is to get important new drugs to the patient earlier by facilitating the development, and expediting the review, of drugs to treat serious conditions and fill an unmet medical need.

Read BioCryst Pharmaceuticals press release